Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Allogene Therapeutics Inc at Cowen IO Next Summit (Virtual) Transcript

Nov 11, 2022 / 04:10PM GMT
Release Date Price: $10.02 (+5.03%)
Tyler Van Buren
Cowen, Inc. - Analyst

All right. Good morning or good afternoon, everyone. My name is Tyler Van Buren, and I'm a Senior Biotech analyst at Cowen. Thank you for joining us for Cowen's Sixth Annual IO Next Summit. For this next session, I'll be moderating a fireside chat with Allogene Therapeutics, a leader and pioneer in the AlloCell therapy space. It's my pleasure to introduce my friend, Eric Schmidt, Allogene's Chief Financial Officer. Eric, thank you for taking the time with us today.

Eric Schmidt
Allogene Therapeutics, Inc. - CFO

Thank you, Tyler. Thanks to Cowen for hosting. Always a pleasure.

Questions & Answers

Tyler Van Buren
Cowen, Inc. - Analyst

(Conference Instructions) Eric, let's go ahead and kick it off with a couple general questions. So the CD19 class of CAR T is annualizing at $2 billion and growing at a significant pace with recent second-line approvals. And then the BCMA class of CAR Ts is launching and will likely create another multibillion class of CAR T. So what's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot